

Q3  2020
QUARTERLY REPORT

DIGNITANA
Clinically superior scalp cooling



**Consistent growth
with increasing
opportunity ahead**

Q3 2020

QUARTERLY REPORT

DIGNITANA

Clinically superior scalp cooling

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING FOR CANCER PATIENTS.

Consistent growth with increasing opportunity ahead

Financial highlights

- Group revenue in Q3 2020 amounted to 12 596 TSEK (10 374 TSEK), an increase of 21 percent over the same period in 2019 and an increase of 6 percent over Q2 2020.
- EBITDA in Q3 2020 amounted to -5 284 TSEK (-6 866 TSEK), a decline of losses of 23 percent over the same period in 2019. Losses increased by 4 percent compared to Q2 2020.
- Earnings per share in Q3 2020 is -0,18 SEK (-0,21 SEK).
- Average Daily Treatment Revenue (ADTR)* was 107 TSEK (101 TSEK), an increase of 7 percent over the same period in 2019 and a decrease of 15 percent compared to Q2 2020.

Significant events during the period

- The Company obtained an unsecured loan from Adma Förvaltnings AB in the amount of 20 MSEK.
- Dignitana announced Redeye is now Certified Adviser.
- The Company appointed Karin Almqvist Liwendahl as new Chief Financial Officer to join Dignitana in November.
- Dignitana was selected as scalp cooling provider by Nuffield Health in United Kingdom.
- Scott McGovern joined Dignitana as Regional Director in Europe to support the Company's expanded focus in this area.
- Dignitana signed an agreement with ION Solutions, a Group Purchasing Organization in the U.S., opening the door to targeted growth within their network of 1100 locations.

Significant events after the period

- The Company announced that the American Medical Association will issue Common Procedural Codes (CPT®) for scalp cooling effective 1 July 2021. This provides a pathway for clinics to utilize reimbursement systems and creates significant opportunity for Dignitana's accelerated growth.
- Dignitana announced that City of Hope selected DigniCap as the scalp cooling provider of choice for its community network of 12 cancer treatment centers in California.

Key Ratios

DIGNITANA GROUP	Q3 2020	Q3 2019	Q1-Q3 2020	Q1-Q3 2019	Full year 2019
Net revenues, TSEK	10 884	9 945	33 701	31 127	40 699
Total revenues, TSEK	12 596	10 374	36 950	32 484	42 546
Net profit after financial items, TSEK	-9 859	-10 146	-32 142	-22 890	-37 950
Cash and bank balances, TSEK	14 796	40 518	14 796	40 518	19 433
Earnings per share before and after dilution, SEK	-0,18	-0,21	-0,58	-0,48	-0,76
Average Daily Treatment Revenue*, TSEK	107	101	117	96	107

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

"We anticipate an improved business environment in 2021 as steady progress is being made toward a safe and effective COVID-19 vaccination. Now, with the pending assignment of CPT codes providing a clear pathway to significantly expand U.S. patient access to scalp cooling, we are more excited about our future growth and opportunity than ever before."

William Cronin, CEO Dignitana AB

Consistent growth with increasing opportunity ahead

2020 has been the most challenging business environment in our company's history. Despite the tremendous and unprecedented disruptions to normal activities that we, our patients and our partners have had to navigate, Dignitana has continued to grow. In the third period the Company showed a 21 percent increase in revenue over the same period of 2019 and a 6 percent revenue increase over the second quarter of 2020. Since the pandemic exploded worldwide in the first period, we have experienced significantly reduced access to our partner sites and in some cases, patient access to our machines was limited or even denied. Our growth this year has been even more impressive given the well-documented reduction in patient diagnoses across multiple malignancies on a year over year basis. However, the pandemic has also given us an opportunity to further reflect on the full extent of our business processes and procedures and make adjustments to optimize our operations moving forward. During this time, we have become a more effective and efficient company that now utilizes state of the art communications tools to strengthen and improve the deep relationships we have cultivated with our clinical partners. Since the pandemic began, we have also added two new sales leaders to our team, including a Director focused on the European market. As announced during the period, Chief Financial Officer Karin Almqvist Liwendahl joined the company in early November and brings broad global finance experience to support Dignitana's growth and rapid expansion. The new hires we have made coupled with improved internal processes and procedures have firmly established the fundamental required to capitalize on the tremendously bright opportunities ahead of us.

DigniCap Delta Drives Growth

We utilize a two-part strategy to drive growth: increase the installed base of devices at additional locations while also increasing utilization rates for those machines. Since introducing the next generation DigniCap Delta a year ago, both of those initiatives have become much easier. DigniCap Delta is technologically advanced, dramatically reduces per patient nursing time and most importantly, patients are seeing extraordinary results even on the toughest chemotherapy regimens. The improvements in usability and patient outcomes with the Delta device are supporting growth and sales around the world.

Progress Toward Reimbursement

After the period, the American Medical Association (AMA) announced the introduction of Common Procedural Codes (CPT®) for scalp cooling which will provide a pathway toward insurance reimbursement for patients in the U.S. While these codes do not take effect until July 1st, we anticipate that this decision will strengthen the level of interest in scalp cooling as we enter 2021. Since our FDA clearance in 2015 we have worked to make scalp cooling accessible for all patients in the U.S., and are pleased to see that the AMA has taken this important step. Now the real work begins as we initiate negotiations with payors to provide consistent coverage to patients for scalp cooling.

Multiplying U.S. Opportunities

Previously I have addressed our U.S. strategy to partner with providers that offer chemotherapy at multiple locations. Many of these multi-site partners are community cancer centers that comprise 70 percent of all cancer treatment locations in the U.S. for the 650,000 patients who receive chemotherapy each year. Volume and revenue drive community cancer centers. When CPT codes for scalp cooling are issued in 2021, these providers will then be able to file for reimbursement from their patient's insurance companies. This will significantly change the conversations we are able to have with practice administrators.

A sub-set of our multi-site providers are Integrated Delivery Networks (IDN), which are large networks of healthcare providers and facilities in specific regions of the U.S.. Among our customers in this focused group, we are seeing twice the standard growth rate in adding new locations and there is tremendous potential with these networks as we initiate discussions about the new CPT code for reimbursement.

In the third period we announced a partnership with ION Solutions, the largest physician service and group purchasing organization specializing in the support of community oncology practices in the U.S., and we are already seeing progress from this agreement. Additionally, American Oncology Network, an alliance of community oncology practice with 45 locations, joined us with a master contract in May. We have made tremendous progress with that group and have now signed 8 of those locations.

Global Support

Global sales diversify reliance on our primary U.S. market. While challenges from COVID-19 led to our first slight decline in U.S. revenue this period, global sales enabled us to continue top line improvement. We added two new markets, Peru and Bahrain, with initial deliveries of DigniCap Delta to both countries in the third period.

Australia remains a strong region for us, supported by the recent addition of a scalp cooling recommendation in the guidance for clinicians that was issued by Cancer Australia. Working closely with Australia distributor Aurora BioScience, we anticipate rapid expansion in the area as we move into 2021.

DigniCap activity in Europe is also increasing with the addition of our new leadership supporting the region, and DigniCap Delta units have been placed for evaluation at several medical centers to demonstrate the clinical superiority of the Delta technology.

Looking ahead

While the challenges from COVID-19 continue to present a more difficult operating environment, our business continues to move forward confidently. The decrease in installations in the second period led to a decline in some key metrics in the third period. However, entering the fourth period we are seeing an increased pace of deliveries and patient utilization is growing again. In very uncertain times, we do know for certain that each day we are making progress and making life better for cancer patients.

The fundamentals of people, product and process required to capitalize on the tremendously bright opportunities ahead of us are all now firmly in place.



A handwritten signature in blue ink that reads "William Cronin". The signature is fluid and cursive, with a large initial 'W'.

William Cronin, CEO
Dignitana AB

The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.


The Company produces the DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues. In 2019 Dignitana received CE Marking and FDA clearance for sales of DigniCap Delta, the next generation scalp cooling device, followed by approvals for the new model in Australia and Israel.

Business model

The Company has five primary revenue streams: treatment fees from patients (pay-per-treatment using leased machines), machine sales, service agreements, leasing fees and product disposables and supplies. In the United States the largest opportunity for growth is through the pay-per-treatment model. For global markets that do not have the pay-per-treatment model, the focus is on creating a more

sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies. The new, single patient, DigniCap Delta is generating significant additional interest from the medical community and we believe the trend towards greater infection control standards will generate additional momentum for the Company going forward.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 12 million incidences of solid tumors diagnosed annually, with more than 1.3 million diagnoses occurring in the U.S. each year. Dignitana estimates that 60 percent of these patients are on regimens compatible with DigniCap. Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with over 1.7 million cases of breast cancer diagnosed annually. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers.

To increase awareness of scalp cooling we work strategically with different organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this. In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world. In the U.S. Dignitana is actively pursuing the pathway to insurance reimbursement for patients and exploring legislative support for this treatment.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. Although COVID-19 restrictions have slowed progress in this area, the Company is currently in discussions to initiate several new studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients.

The DigniCap Scalp Cooling System is currently available in 40 countries. The DigniCap C3 device has been marketed worldwide since 2009. DigniCap Delta received CE Marking and U.S. FDA clearance followed by TGA (Australia) clearance in 2019. The transition to DigniCap Delta is underway with current U.S. customers and the roster of new U.S. customers is growing rapidly. Outside the U.S., the next generation DigniCap Delta is already in use in Australia, Italy, Spain, the United Kingdom and Israel, Bahrain, Peru and Germany.



Financial information and comments

Revenue – Dignitana Group

Our transition to the new Delta unit and business model continue now with just over 72 percent of our U.S sites having at least one Delta device and units being shipped to more sites overseas. Group revenues are generated by direct sales of systems, pay-per-treatment fees, cap and patient kit sales, leased systems, service agreements and other revenue. Dignitana Group total revenue and other income during the third quarter 2020 amounted to 12 596 TSEK, which is a increase of 21 percent compared to the same period last year. Dignitana revenue and costs are comprised of different currencies such as U.S. Dollars, Euros, SEK, and other currencies. Foreign exchange translation differences are found on the Income Statement in Other Income, Other Operating Expenses and Financial Income and Expenses. Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. market, Dignitana does not sell devices directly to the end customer as various lease models are employed. Cost of goods sold for the Group was -4 116 TSEK for the third quarter of 2020. Gross margin for the first three quarters of 2020 increased compared to the same period previous year.

Profit and Loss – Dignitana Group

Group EBIT for the third quarter was -9 458 TSEK compared to -9 923 TSEK in the same period in 2019. Net profit after financial items was -9 859 TSEK compared to -10 146 TSEK for the same period last year. The improvement in EBIT was from decreased operating expenses for travel, trade shows and accounting which offset higher personnel expenses.

Earnings per share for the third quarter of 2020 amount to -0,18 SEK, which is a slight improvement compared with the third quarter of 2019.

Cash flow and liquidity

At close of the period the Group's cash position was 14 796 TSEK. The Board of Directors and management are continually and actively working to safeguard liquidity and the continued financing of operations under the most advantageous terms possible.



Revenue – Dignitana Parent Company

Dignitana Parent Company total revenues during the third quarter amounted to 9 092 TSEK which is a increase of 38 percent compared to the same period last year. Other Income includes foreign exchange gains on accounts receivable and accounts payable and the revenue associated with the sublease of a portion of the Lund office space.

Profit and Loss – Dignitana Parent Company

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. market Dignitana does not sell the device directly to the end customer as various lease models are employed.

Cost of goods sold for the Parent Company increased to -2 578 TSEK for the third quarter 2020. For the first three quarters of 2020 the cost of goods sold was -5 578 TSEK which is an increase compared to the same period previous year, -4 893 TSEK.

Parent EBIT for the third quarter was -5 339 TSEK compared to -5 870 TSEK in the same period in 2019.

Net profit after financial items was -5 335 TSEK compared to -6 104 TSEK for the same period last year. Despite an increase in depreciation and amortization, losses have declined due to lower operating expenses, showing the same trend as for the Group.

Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The nonconclusive list of the Company's risks concerns include but are not limited to: Patents, Key Personnel, Growth, Management, Restructuring, Development Costs, Competitors, Dependence on Individual Customers, Customers, Authorization and Registration, Chemotherapy Without Side Effects, Distributors and Manufacturers, Profitability and Future Capital Needs, Political Risk, Pandemic Risk, Regulatory or Change of Laws, Disputes and Currency Risks.

For a detailed explanation of these risk factors view the 2019 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements". Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Staff

During the third quarter Dignitana had, on average, 27 persons employed.

The share

The total number of outstanding shares is 55 059 155 and earnings per share is -0,18 SEK. The share has been listed on Nasdaq First North Growth Market in Stockholm since 30 November 2011 after having been listed at Spotlight Market in Stockholm since June 2009. It is traded under the DIGN ticker.

At the Extraordinary General Shareholders meeting in February 2020 it was resolved to issue and transfer

warrants to key persons in Dignitana Inc. in accordance with the proposal by the Board of Directors. If all the warrants outstanding under the 2017/2020 program would be converted in full the total dilution in number of shares and votes is approximately 4,5 percent. Warrants are given free of charge and costs will be incurred in the fourth period of 2020.

Redeye is the Company's Certified Adviser.

Largest Shareholders

30 SEPTEMBER 2020	HOLDINGS	PERCENTAGE
ADMA FÖRVALTNINGS AB (Greg Dingizian)	15 250 000	27,70 %
FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION	4 462 094	8,10 %
CBLDN-UBS FINANCIAL SERVICES (William Cronin & others)	4 245 739	7,71 %
EUROSUND AB (Johan Stormby)	3 046 036	5,53 %
SKANDIA, FÖRSÄKRINGS (Greg Dingizian & others)	1 951 675	3,54 %
POURSAMAD, AMIR	1 520 095	2,76 %
NORDNET PENSIONS FÖRSÄKRING AB	1 064 075	1,93 %
RÜLF, SEMMY	1 015 058	1,84 %
PERSSON, RUTGER	990 310	1,80 %
STRAND, PETER	800 000	1,45 %
TOTAL	34 345 082	62,38 %
OTHER SHAREHOLDERS	20 714 073	37,62 %
TOTAL	55 059 155	100 %

Source: Euroclear

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 19 November 2020

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Board member and CEO

Richard Dilorio
Board member

Ingrid Atteryd Heiman
Board member

Pontus Kristiansson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

This interim report has not
been audited by the Company auditors.

Income Statement – Dignitana Group, SEK

DIGNITANA GROUP	Q3 2020	Q3 2019	Q1-Q3 2020	Q1-Q3 2019	Full year 2019
Operating Income					
Revenue	10 884 416	9 944 887	33 700 678	31 126 797	40 699 211
Own work capitalized	0	0	0	0	0
Other income	1 712 019	429 338	3 248 969	1 356 757	1 846 817
Total Operating Income	12 596 435	10 374 225	36 949 647	32 483 554	42 546 028
Cost of Goods Sold					
Goods for Resale	-4 116 353	-3 185 815	-9 691 599	-8 721 981	-11 559 218
Gross profit	8 480 082	7 188 410	27 258 048	23 761 573	30 986 810
Expenses					
Operating expense	-6 008 902	-8 650 985	-23 310 572	-23 324 159	-34 984 714
Personnel expense	-5 824 372	-5 087 412	-19 277 405	-15 003 432	-21 367 162
Other operating expenses	-1 931 425	-315 513	-3 782 546	-264 274	-894 891
Total operating expenses	-13 764 699	-14 053 910	-46 370 524	-38 591 865	-57 246 767
Operating profit (loss) - EBITDA	-5 284 617	-6 865 500	-19 112 476	-14 830 292	-26 259 957
Depreciation of tangible and intangible assets	-4 173 166	-3 057 409	-11 856 609	-6 907 768	-10 266 997
Operating profit (loss) after depreciation - EBIT	-9 457 782	-9 922 909	-30 969 085	-21 738 060	-36 526 954
Result from financial investments					
Interest income and similar items	107 080	81 326	138 686	82 808	102 590
Interest expenses and similar items	-508 197	-304 011	-1 311 813	-1 234 306	-1 525 440
Total income from financial investments	-401 117	-222 685	-1 173 128	-1 151 498	-1 422 850
Net profit after financial items	-9 858 899	-10 145 594	-32 142 212	-22 889 558	-37 949 804
Corporate Taxes	0	-24 837	0	-82 241	-85 413
Results for the Period	-9 858 899	-10 170 431	-32 142 212	-22 971 799	-38 035 217

Balance Sheet – Dignitana Group, SEK

DIGNITANA GROUP	2020-09-30 2020	2019-09-30 2019	Full year 2019
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development, net	18 016 088	24 620 362	22 594 795
<u>Tangible assets</u>			
Equipment, tools and installations, net	30 883 582	14 879 124	22 214 084
Total Fixed Assets	48 899 670	39 499 486	44 808 879
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	7 564 279	7 596 011	9 391 105
Advance payment to suppliers	2 798 327	0	0
<u>Current Receivables</u>			
Accounts Receivable	4 498 022	6 106 795	4 409 995
Current Tax Assets	9 084	463 499	269 467
Other Current Receivables	1 380 580	407 410	844 666
Prepaid expenses and accrued income	992 059	956 672	2 331 781
Cash and Bank Balances	14 796 195	40 517 844	19 432 901
Total Current Assets	32 038 546	56 048 231	36 679 915
Total Assets	80 938 216	95 547 717	81 488 794
EQUITY AND LIABILITIES			
Equity			
<u>Restricted equity</u>			
Share Capital			
(55 059 155 shares par value SEK 1, previous year 40 528 224)	55 059 155	55 059 155	55 059 155
Unregistered share capital	0	0	0
Fund for development expenses	16 718 672	20 514 693	19 218 072
<u>Non-restricted equity</u>			
Other non-restricted equity	-15 143 021	16 974 547	18 860 805
Results for the period	-32 142 212	-22 971 799	-38 035 217
Total Equity	24 492 594	69 576 596	55 102 816
Long Term Liabilities			
Other long term liabilities	3 609 516	3 000 581	1 917 208
Total Long Term Liabilities	3 609 516	3 000 581	1 917 208
Current Liabilities			
Accounts payable	11 832 756	8 593 471	8 888 418
Other current liabilities	23 981 338	1 621 405	3 401 023
Liabilities to credit institutions	9 485 781	7 610 643	5 505 968
Accrued expenses and deferred income	7 536 232	5 145 021	6 673 362
Total current liabilities	52 836 106	22 970 540	24 468 771
Total liabilities	56 445 622	25 971 121	26 385 979
Total Equity and Liabilities	80 938 216	95 547 717	81 488 794

Changes in Equity – Dignitana Group, SEK

DIGNITANA GROUP	Q1-Q3 2020	Q1-Q3 2019	Full year 2019
Opening balance	55 102 816	54 965 116	54 965 116
New Share Issue	0	41 990 000	41 990 000
Warrants	189 000	0	0
Issue expenses	218 010	-3 380 915	-3 380 915
Translation difference on consolidation	1 124 981	-1 025 806	-436 168
Results through the end of the period	-32 142 212	-22 971 799	-38 035 217
Closing balance	24 492 594	69 576 596	55 102 816

Statement of Cash Flows – Dignitana Group, SEK

DIGNITANA GROUP	Q3 2020	Q3 2019	Q1-Q3 2020	Q1-Q3 2019	Full year 2019
Operating Activities					
Operating income before financial items	-9 457 782	-9 922 909	-30 969 085	-21 738 060	-36 526 954
Adjustments for items not affecting cash flows	4 845 519	3 057 409	12 528 962	6 907 768	9 666 997
Interest received	-30 302	81 326	535	82 807	102 589
Interest paid	-612 640	-304 011	-1 311 813	-1 234 306	-1 525 440
Income tax paid	0	0	0	-421 886	-425 058
	-5 255 205	-7 088 185	-19 751 401	-16 403 677	-28 707 866
Changes in inventories	-838 022	-1 674 292	-1 019 494	-1 287 475	-3 082 569
Changes in other current receivables	-823 122	-1 043 405	309 093	389 122	467 589
Changes in other current liabilities	20 901 928	460 702	24 695 520	-139 564	3 988 327
Cash flows from operating activities	15 631 823	-9 345 180	4 233 718	-17 441 594	-27 334 519
Investing Activities					
Acquisition of fixed assets	-5 373 501	-4 416 183	-16 630 981	-12 630 748	-20 699 370
Cash flows from investing activities	-5 373 501	-4 416 183	-16 630 981	-12 630 748	-20 699 370
Financing activities					
New share issue	0	41 990 000	0	51 836 053	51 836 053
Issuance costs	0	-3 380 915	218 010	-3 905 915	-3 905 915
Warrants	0	0	189 000	0	0
Liabilities to credit institutions	-3 144 637	4 256 118	6 203 306	423 386	-2 764 662
Cash flows from financial activities	-3 144 637	42 865 203	6 610 316	48 353 524	45 165 476
Cash flows in the period	7 113 685	29 103 840	-5 786 947	18 281 182	-2 868 413
Cash and cash equivalents at start of the period	7 483 745	11 468 142	19 432 901	22 160 875	22 160 875
Translation difference on cash and cash equivalents	198 765	-54 138	1 150 242	75 786	140 439
Cash and cash equivalents Period End	14 796 195	40 517 844	14 796 195	40 517 844	19 432 901

Income Statement – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	Q3 2020	Q3 2019	Q1-Q3 2020	Q1-Q3 2019	Full year 2019
Operating Income					
Revenue	7 415 857	6 166 270	22 762 083	20 740 840	27 114 785
Own work capitalized	0	0	0	0	0
Other income	1 676 474	429 338	3 381 728	1 356 757	1 846 817
Total Operating Income	9 092 331	6 595 608	26 143 811	22 097 597	28 961 602
Cost of Goods Sold					
Goods for Resale	-2 578 865	-1 811 012	-5 577 722	-4 893 481	-6 001 626
Gross profit	6 513 466	4 784 596	20 566 089	17 204 116	22 959 976
Expenses					
Operating expense	-5 511 397	-7 347 401	-20 502 599	-22 835 114	-33 682 777
Personnel expense	-476 901	-324 744	-1 496 182	-1 271 259	-1 573 393
Other operating expenses	-1 756 832	-859	-3 599 213	50 380	-580 237
Total operating expenses	-7 745 130	-7 673 004	-25 597 994	-24 055 993	-35 836 407
Operating profit (loss) - EBITDA	-1 231 664	-2 888 408	-5 031 905	-6 851 877	-12 876 431
Depreciation of tangible and intangible assets	-4 106 927	-2 981 997	-11 642 121	-6 679 235	-9 950 466
Operating profit (loss) after depreciation - EBIT	-5 338 591	-5 870 405	-16 674 026	-13 531 112	-22 826 897
Result from financial investments					
Interest income and similar items	137 924	0	137 924	0	0
Interest expenses and similar items	-133 998	-233 548	-255 535	-721 357	-734 977
Total income from financial investments	3 926	-233 548	-117 611	-721 357	-734 977
Net profit after financial items	-5 334 665	-6 103 953	-16 791 637	-14 252 469	-23 561 874
Corporate Taxes	0	0	0	0	0
Results for the Period	-5 334 665	-6 103 953	-16 791 637	-14 252 469	-23 561 874

Balance Sheet – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	2020-09-30 2020	2019-09-30 2019	Full year 2019
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development, net	17 986 726	24 584 632	22 561 837
<u>Tangible assets</u>			
Equipment, tools and installations, net	30 544 505	14 381 425	21 719 293
<u>Financial assets</u>			
Participations in group companies	522 094	522 094	522 094
Long Term Receivable from group companies	449 415	490 235	0
Total Fixed Assets	49 502 740	39 978 386	44 803 224
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	6 333 053	6 585 195	8 473 678
Advance payment to suppliers	2 798 327	0	0
<u>Current Receivables</u>			
Accounts Receivable	1 135 619	1 189 619	1 277 591
Current Receivables from group companies	13 440 770	336 882	7 366 642
Current Tax Assets	9 084	463 499	314 450
Other Current Receivables	1 138 592	390 408	831 934
Prepaid expenses and accrued income	414 044	420 100	501 518
Cash and Bank Balances	11 075 378	39 172 147	17 116 918
Total Current Assets	34 347 782	48 557 850	35 882 731
Total Assets	85 847 607	88 536 236	80 685 955
EQUITY AND LIABILITIES			
Equity			
<u>Restricted equity</u>			
Share Capital			
(55,059,155 shares par value SEK 1, previous year 40,528,224)	55 059 155	55 059 155	55 059 155
Unregistered share capital	0	0	0
Fund for development expenses	16 718 672	20 514 693	19 218 072
<u>Non-restricted equity</u>			
Retained earnings	-72 882 308	-61 860 400	-51 819 834
Share premium reserves	83 783 504	83 594 504	83 594 504
Issue expense	-11 906 850	-3 380 915	-12 124 860
Results for the period	-16 791 637	-14 252 469	-23 561 874
Total Equity	53 980 536	79 674 568	70 365 163
Current Liabilities			
Accounts payable	8 321 323	4 830 363	4 923 861
Other current liabilities	20 133 616	0	205 693
Liabilities to credit institutions	0	0	0
Current payable to group company	0	-196 686	0
Accrued expenses and deferred income	3 412 132	4 227 991	5 191 238
Total current liabilities	31 867 071	8 861 668	10 320 792
Total liabilities	31 867 071	8 861 668	10 320 792
Total Equity and Liabilities	85 847 607	88 536 236	80 685 955

Policies for preparation of the financial report

Swedish Annual Accounts Act (1995:1554) and Swedish Accounting Standards Board General Recommendations BFNAR 2012:1 Annual reporting and consolidated financial statements.

Financial calendar

18 February 2021	2020 Year End Report
8 April 2021	2020 Annual Report
20 May 2021	Q1 Report
20 May 2021	Annual General Meeting
19 August 2021	Q2 Report
18 November 2021	Q3 Report
17 February 2022	2021 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.se
investorrelations@dignitana.com
www.dignitana.se

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se